NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
03 Janvier 2017 - 1:00PM
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical
company developing drugs for central nervous system (CNS) diseases,
today announced that CEO Oded S. Lieberman, PhD will present at the
35th Annual J.P. Morgan Healthcare Conference on Thursday, January
12 at 10:30 am PT / 1:30 pm ET in San Francisco. Dr.
Lieberman will give a corporate overview and discuss the company's
flagship product candidates designed to treat moderate to severe
Parkinson's disease.
To access the live webcast of the presentation,
please visit ir.neuroderm.com/. A replay will be available
for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical
company developing central nervous system (CNS) product candidates
that are designed to overcome major deficiencies of current
treatments and achieve enhanced clinical efficacy through
continuous, controlled administration. The Company has three
product candidates in different stages of development which offer a
solution for almost every Parkinson’s disease patient from the
moderate to the very severe stage of the disease. The Company
has developed a line of levodopa and carbidopa (LD/CD) product
candidates administered through small belt pumps that deliver a
continuous, controlled dose of LD/CD. The LD/CD product
candidate in low dose and high dose form (ND0612L and ND0612H), are
used for the treatment of moderate and advanced Parkinson’s disease
patients, respectively, and are delivered subcutaneously. In
addition, NeuroDerm is developing ND0701, a novel subcutaneously
delivered apomorphine formulation for patients who suffer from
moderate to severe Parkinson’s disease and who do not respond well
to LD/CD. NeuroDerm is headquartered in the Weizmann Science
Park in Rehovot, Israel.
NeuroDerm Contact:Oded S.
Lieberman, PhD, CEOoded@neuroderm.comTel.: +972-8-946 2729; Cell:
+1-617-517 6077
U.S. Investor Contact:David
CareyLazar Partners Ltd.dcarey@lazarpartners.com+212-867-1768
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Neuroderm Ltd. - Ordinary Shares (NASDAQ): 0 recent articles
Plus d'articles sur